- Home
- ETV vs ARQT Comparison
ETV vs ARQT Comparison
Compare ETV & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- ARQT
- Stock Information
- Founded
- ETV 2005
- ARQT 2016
- Country
- ETV United States
- ARQT United States
- Employees
- ETV N/A
- ARQT N/A
- Industry
- ETV Investment Managers
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- ETV Finance
- ARQT Health Care
- Exchange
- ETV Nasdaq
- ARQT Nasdaq
- Market Cap
- ETV 1.6B
- ARQT 1.7B
- IPO Year
- ETV N/A
- ARQT 2020
- Fundamental
- Price
- ETV $13.39
- ARQT $13.82
- Analyst Decision
- ETV
- ARQT Strong Buy
- Analyst Count
- ETV 0
- ARQT 6
- Target Price
- ETV N/A
- ARQT $18.80
- AVG Volume (30 Days)
- ETV 252.5K
- ARQT 2.0M
- Earning Date
- ETV 01-01-0001
- ARQT 08-13-2025
- Dividend Yield
- ETV 8.75%
- ARQT N/A
- EPS Growth
- ETV N/A
- ARQT N/A
- EPS
- ETV N/A
- ARQT N/A
- Revenue
- ETV N/A
- ARQT $212,819,000.00
- Revenue This Year
- ETV N/A
- ARQT $61.15
- Revenue Next Year
- ETV N/A
- ARQT $37.98
- P/E Ratio
- ETV N/A
- ARQT N/A
- Revenue Growth
- ETV N/A
- ARQT 100.03
- 52 Week Low
- ETV $11.05
- ARQT $7.86
- 52 Week High
- ETV $13.50
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- ETV 49.38
- ARQT 50.73
- Support Level
- ETV $13.45
- ARQT $12.97
- Resistance Level
- ETV $13.64
- ARQT $13.84
- Average True Range (ATR)
- ETV 0.13
- ARQT 0.61
- MACD
- ETV -0.04
- ARQT 0.02
- Stochastic Oscillator
- ETV 11.29
- ARQT 51.64
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.